Know Labs’ revolutionary technology platform is changing how we can analyze molecules non-invasively. Know Labs is a public-traded company (NYSE American: $KNW)
Today we announced the interim results from our latest clinical research study. We will present the results of the study at the 17th International @ATTDconf in Florence, Italy on March 6-9, 2024. knowlabs.co/post/know-labs-n…
Today, we announce the KnowU™, our non-invasive wearable CGM that incorporates the sensor we plan to submit to the FDA for clearance. We’re now closer to bringing the device to the global marketplace and providing equitable care in #diabetes management youtube.com/watch?v=9ohXLeh0…
We're returning to this year’s Bernstein CGM Disruptors Conference, where our CFO and SVP of IP, Pete Conley, will present significant updates on our progress over the past year and our path to FDA clearance.
Read the full announcement here: knowlabs.co/post/know-labs-p…
Our CEO and Chairman, @ronerickson was featured in Authority Magazine’s "The Future is Now: Exciting Emerging Technology". The article covers Ron’s storied career and how Know Labs’ novel technology could be the future standard of patient care. Read here: medium.com/authority-magazin…
Our Chief Medical Officer, Dr. James (Andy) Anderson recently spoke with Sarah Glinski and @forbeshealth about diet and lifestyle changes effective for treating insulin resistance. Read the article to learn more: forbes.com/health/conditions…
Today we released the results of a new study demonstrating that continued algorithm refinement and more high-quality data improved the accuracy of our Bio-RFID technology.
Learn more about the study here: knowlabs.co/research-and-val…
Our CEO and Chairman, @ronerickson wrote an article for @Forbes on how better, earlier detection and diagnosis of prediabetes could prevent the growing incidence of type 2 diabetes, especially among people 20 years old or younger.
forbes.com/sites/forbestechc…
Know Labs recently unveiled the prototype for its non-invasive, portable glucose monitoring device. The device incorporates the company’s proprietary body-radio frequency identification (Bio-RFID) technology — meaning its sensors deploy radio waves... ow.ly/QKfF104K8YF
Announcing our Generation 1 Prototype – a big step forward as we work toward developing the first FDA-cleared, non-invasive glucose monitoring device.
Learn more here: knowlabs.co/post/know-labs-c…
Today we released the results of a new study that demonstrates improved accuracy for our Bio-RFID technology in predicting blood glucose, using the Dexcom G6® as a reference device.
Learn more about the study here: knowlabs.co/research-and-val…#medicaldevices#glucosemonitoring
We’re excited to share that our CFO and SVP of IP, Pete Conley, will be speaking on the “Make Your CFO an IP Believer” panel at the 2023 #IPBCGlobal to discuss the importance of strategic #IP development in maximizing shareholder value. Read more here: knowlabs.co/post/know-labs-j…
We are thrilled to announce our first peer-reviewed publication in the scientific journal, Sensors MDPI, of our proof-of-principle study conducted in collaboration with the @MayoClinic!
Read the full manuscript here: mdpi.com/1424-8220/23/10/481…
Our CEO and Chairman, @ronerickson wrote an article for @Forbes on how emerging technologies will increase access, lead to better, more cost-effective treatment options and help to democratize healthcare.
forbes.com/sites/forbestechc…
A writeup in @Benzinga today covers our partnership with @EdgeImpulse and showcases our work as a prime example for how responsible ML applications can significantly improve healthcare diagnostics. benzinga.com/general/biotech…
Know Labs Provides Update on Strategic Partners Engaged in Data Science, Product Engineering and Regulatory Affairs to Accelerate Progress Toward FDA Application
businesswire.com/news/home/2…